{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:44:36Z","timestamp":1782708276357,"version":"3.54.5"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"12","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Seven new 4-[2-(dichloromethyl)pyrazolo[1,5-a][1,3,5]triazine\nderivatives were investigated for anticancer activity, possible molecular mechanisms of\nanticancer action, and ADMET properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The 4-benzenesulfonamide derivatives of pyrazolo[1,5-a][1,3,5]triazine were\nsynthesized using the condensation of N-(2,2-dichloro-1-cyanovinyl)-amides IV with\n1H-pyrazol-5-amine. Compound antitumor activities were evaluated using the NCI-60\nhuman cancer cell line. AutoDockTools and AutoDock Vina software were used for\nmolecular modeling. Using the ADMETlab 3.0 and pkCSM web sources, the ADMET\nproperties of compounds 4, 5, and 7 were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seven new pyrazolo[1,5-a][1,3,5]triazine derivatives were synthesized. The\ncompounds 4, 5, and 7 exhibit high activity &gt;1 \u03bcM against leukemia, colon, and renal\ncancer. Compound 4 exhibited the most potent activity, with IC50 values\nof 0.32 \u03bcM against leukemia, 0.49-0.89 \u03bcM against colon cancer, and 0.92 \u03bcM against\nrenal cancer. Molecular modeling has demonstrated a potential antitumor mechanism involving\nCDK. The predicted ADMET profile of compounds 4, 5, and 7 is favorable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The seven novel pyrazolo[1,5-a][1,3,5]triazines, as purine bioisosteres,\nwere developed, synthesized, and investigated by in vitro and in silico methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Seven novel pyrazolo[1,5-a][1,3,5]triazine derivatives exhibited anticancer\nactivity against the NCI-60 cancer cell lines. The compounds 4, 5, and 7 demonstrated\nstrong anticancer activity, with growth inhibition (GI) values exceeding 50% across all\nnine cancer types tested. The most active compound, 4, is against leukemia, colon cancer,\nrenal cancer, and lung cancer. All compounds exhibit low toxicity, with LC50 values\nof 100 \u03bcM or greater. The molecular docking of compounds 4, 5, and 7 revealed the\npotential to inhibit cancer-associated cyclin-dependent kinases. The predicted ADMET\nprofiles of their compounds are favorable, providing a basis for further improvement of\ntheir anticancer activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673385989250711112625","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:12:56Z","timestamp":1754302376000},"page":"2406-2420","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New 4-Benzenesulfonamide Derivatives of Pyrazolo[1,5-a][1,3,5] triazine as Purine Bioisosteres: Development, Synthesis, and Anticancer Perspective"],"prefix":"10.2174","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-3692","authenticated-orcid":true,"given":"Ivan","family":"Semenyuta","sequence":"first","affiliation":[{"name":"Department of Chemistry Bioactive Nitrogen-containing Heterocyclic Bases, V.P. KukharInstitute ofBioorganic Chemistry and Petrochemistry, Kyiv, 02094, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7089-1393","authenticated-orcid":true,"given":"Stepan","family":"Pilyo","sequence":"additional","affiliation":[{"name":"Department of Chemistry Bioactive Nitrogen-containing Heterocyclic Bases, V.P. KukharInstitute ofBioorganic Chemistry and Petrochemistry, Kyiv, 02094, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-3796","authenticated-orcid":true,"given":"Bohdan","family":"Demydchuk","sequence":"additional","affiliation":[{"name":"Department of Chemistry Bioactive Nitrogen-containing Heterocyclic Bases, V.P. KukharInstitute ofBioorganic Chemistry and Petrochemistry, Kyiv, 02094, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-1845","authenticated-orcid":true,"given":"Oleksandr","family":"Lyavinets","sequence":"additional","affiliation":[{"name":"Department of General Chemistry andChemistry of Materials, Yuriy Fedkovych Chernivtsi National University, Chernivtsi, 58012, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-3412","authenticated-orcid":true,"given":"Volodymyr","family":"Brovarets","sequence":"additional","affiliation":[{"name":"Department of Chemistry Bioactive Nitrogen-containing Heterocyclic Bases, V.P. KukharInstitute ofBioorganic Chemistry and Petrochemistry, Kyiv, 02094, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.devcel.2008.01.013","volume":"14","author":"Besson A.","year":"2008","unstructured":"Besson A.; Dowdy S.F.; Roberts J.M.; CDK inhibitors: Cell cycle regulators and beyond. Dev Cell  2008,14(2),159-169","journal-title":"Dev Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/ijms22062935","volume":"22","author":"\u0141ukasik P.","year":"2021","unstructured":"\u0141ukasik P.; Za\u0142uski M.; Gutowska I.; Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review. Int J Mol Sci  2021,22(6),2935","journal-title":"Int J Mol Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1128\/MCB.00253-09","volume":"30","author":"Adon A.M.","year":"2010","unstructured":"Adon A.M.; Zeng X.; Harrison M.K.; Sannem S.; Kiyokawa H.; Kaldis P.; Saavedra H.I.; CDK2 and CDK4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol  2010,30(3),694-710","journal-title":"Mol Cell Biol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"774845","DOI":"10.3389\/fcell.2021.774845","volume":"9","author":"Fagundes R.","year":"2021","unstructured":"Fagundes R.; Teixeira L.K.; Cyclin E\/CDK2: DNA replication, replication stress and genomic instability. Front Cell Dev Biol  2021,9,774845","journal-title":"Front Cell Dev Biol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","volume":"25","author":"Tadesse S.","year":"2020","unstructured":"Tadesse S.; Anshabo A.T.; Portman N.; Lim E.; Tilley W.; Caldon C.E.; Wang S.; Targeting CDK2 in cancer: Challenges and opportunities for therapy. Drug Discov Today  2020,25(2),406-413","journal-title":"Drug Discov Today"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","volume":"17","author":"Wang L.","year":"2021","unstructured":"Wang L.; Shao X.; Zhong T.; Wu Y.; Xu A.; Sun X.; Gao H.; Liu Y.; Lan T.; Tong Y.; Tao X.; Du W.; Wang W.; Chen Y.; Li T.; Meng X.; Deng H.; Yang B.; He Q.; Ying M.; Rao Y.; Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat Chem Biol  2021,17(5),567-575","journal-title":"Nat Chem Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12935-022-02747-z","volume":"22","author":"Ghafouri-Fard S.","year":"2022","unstructured":"Ghafouri-Fard S.; Khoshbakht T.; Hussen B.M.; Dong P.; Gassler N.; Taheri M.; Baniahmad A.; Dilmaghani N.A.; A review on the role of cyclin dependent kinases in cancers. Cancer Cell Int  2022,22(1),325","journal-title":"Cancer Cell Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","volume":"78","author":"Caruso J.A.","year":"2018","unstructured":"Caruso J.A.; Duong M.T.; Carey J.P.W.; Hunt K.K.; Keyomarsi K.; Low-molecular-weight cyclin E in human cancer: Cellular consequences and opportunities for targeted therapies. Cancer Res  2018,78(19),5481-5491","journal-title":"Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/0929867321666141106113633","volume":"22","author":"Chohan T.","year":"2014","unstructured":"Chohan T.; Qian H.; Pan Y.; Chen J.Z.; Cyclin-dependent kinase-2 as a target for cancer therapy: Progress in the development of CDK2 inhibitors as anti-cancer agents. Curr Med Chem  2014,22(2),237-263","journal-title":"Curr Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"107841","DOI":"10.1016\/j.bioorg.2024.107841","volume":"153","author":"Shah A.","year":"2024","unstructured":"Shah A.; Teraiya N.; Kamdar J.H.; Juneja T.; Sangani C.B.; Ahmed S.; Kapadiya K.; Novel purine derivatives as selective CDK2 inhibitors with potential anticancer activities: Design, synthesis and biological evaluation. Bioorg Chem  2024,153,107841","journal-title":"Bioorg Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3978\/j.issn.2305-5839.2015.03.61","volume":"3","author":"Cicenas J.","year":"2015","unstructured":"Cicenas J.; Kalyan K.; Sorokinas A.; Stankunas E.; Levy J.; Meskinyte I.; Stankevicius V.; Kaupinis A.; Valius M.; Roscovitine in cancer and other diseases. Ann Transl Med  2015,3(10),135","journal-title":"Ann Transl Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/ijms22062806","volume":"22","author":"\u0141ukasik P.","year":"2021","unstructured":"\u0141ukasik P.; Baranowska-Bosiacka I.; Kulczycka K.; Gutowska I.; Inhibitors of cyclin-dependent kinases: Types and their mechanism of action. Int J Mol Sci  2021,22(6),2806","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7124\/bc.000A21","volume":"36","author":"Velihina Y.S.","year":"2020","unstructured":"Velihina Y.S.; Pil\u2019o S.G.; Zyabrev V.S.; Moskvina V.S.; Shablykina O.V.; Brovarets V.S.; 2-(Dichloromethyl)pyrazolo[1,5-a][1,3,5]triazines: Synthesis and anticancer activity. Biopolim Kletka  2020,36(1),60-73","journal-title":"Biopolim Kletka"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5267\/j.ccl.2024.8.001","volume":"14","author":"Severin O.","year":"2025","unstructured":"Severin O.; Pilyo S.; Semenyuta I.; Kachaeva M.; Zhirnov V.; Brovaret V.; Design, synthesis and anticancer activity of novel 4-(5-amino-4-cyano-1,3-oxazol-2-yl)benzenesulfonamide derivative. Current Chemistry Letters  2025,14(1),159-172","journal-title":"Current Chemistry Letters"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ddr.430340203","volume":"34","author":"Boyd M.R.","year":"1995","unstructured":"Boyd M.R.; Paull K.D.; Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res  1995,34(2),91-109","journal-title":"Drug Dev Res"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-8152-9_2","author":"Boyd M.R.","year":"1997","unstructured":"Boyd M.R.; The NCI in vitro anticancer drug discovery screen. Anticancer Drug Development Guide Cancer Drug Discovery and Development  1997","journal-title":"Anticancer Drug Development Guide Cancer Drug Discovery and Development"},{"key":"ref=17","unstructured":"Marvin Sketch 5.5.0.1.  Available from:  https:\/\/www.chemaxon.com"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"Hanwell M.D.","year":"2012","unstructured":"Hanwell M.D.; Curtis D.E.; Lonie D.C.; Vandermeersch T.; Zurek E.; Hutchison G.R.; Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J Cheminform  2012,4(1),17","journal-title":"J Cheminform"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; Sanner M.F.; Belew R.K.; Goodsell D.S.; Olson A.J.; AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem  2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"Eberhardt J.","year":"2021","unstructured":"Eberhardt J.; Santos-Martins D.; Tillack A.F.; Forli S.; AutoDock vina 1.2.0: New docking methods, expanded force field, and python bindings. J Chem Inf Model  2021,61(8),3891-3898","journal-title":"J Chem Inf Model"},{"key":"ref=21","unstructured":"Discovery Studio Visualizer.  Available from:  https:\/\/discover.3ds.com\/"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"W422","DOI":"10.1093\/nar\/gkae236","volume":"52","author":"Fu L.","year":"2024","unstructured":"Fu L.; Shi S.; Yi J.; Wang N.; He Y.; Wu Z.; Peng J.; Deng Y.; Wang W.; Wu C.; Lyu A.; Zeng X.; Zhao W.; Hou T.; Cao D.; ADMETlab 3.0: An updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res  2024,52(W1),W422-W431","journal-title":"Nucleic Acids Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"Pires D.E.V.","year":"2015","unstructured":"Pires D.E.V.; Blundell T.L.; Ascher D.B.; pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem  2015,58(9),4066-4072","journal-title":"J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.33609\/2708-129X.86.5.2020.53-62","volume":"86","author":"Velihina Y.","year":"2020","unstructured":"Velihina Y.; Kachaeva M.; Pil\u2019o S.; Moskvina V.; Shablykina O.; Brovarets V.; Synthesis of 4-hetaryl-2- (dichloromethyl)pyrazolo[1,5-a][1,3,5]-triazines. J Chem Ukrainian  2020,86(5),53-62","journal-title":"J Chem Ukrainian"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.15407\/dopovidi2019.07.075","volume":"7","author":"Velihina Y. S.","year":"2019","unstructured":"Velihina Y. S.; Pil\u2019o S. G.; Zyabrev V. S.; Brovarets V.S.; Synthesis and evaluation of the antiviral activity of 2-(dichloromethyl)pyrazolo[1,5-a][1,3,5]triazines. Rep Natl Acad Sci Ukr  2019,7(7),75-80","journal-title":"Rep Natl Acad Sci Ukr"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"103239","DOI":"10.1016\/j.bioorg.2019.103239","volume":"92","author":"Oudah K.H.","year":"2019","unstructured":"Oudah K.H.; Najm M.A.A.; Samir N.; Serya R.A.T.; Abouzid K.A.M.; Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors. Bioorg Chem  2019,92,103239","journal-title":"Bioorg Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"Berman H.M.","year":"2000","unstructured":"Berman H.M.; Westbrook J.; Feng Z.; Gilliland G.; Bhat T.N.; Weissig H.; Shindyalov I.N.; Bourne P.E.; The protein data bank. Nucleic Acids Res  2000,28(1),235-242","journal-title":"Nucleic Acids Res"},{"key":"ref=28","first-page":"1913","volume":"11","author":"Zhang M.","year":"2021","unstructured":"Zhang M.; Zhang L.; Hei R.; Li X.; Cai H.; Wu X.; Zheng Q.; Cai C.; CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res  2021,11(5),1913-1935","journal-title":"Am J Cancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/1568009623666230320144713","volume":"23","author":"Mounika P.","year":"2023","unstructured":"Mounika P.; Gurupadayya B.; Kumar H.Y.; Namitha B.; An overview of CDK enzyme inhibitors in cancer therapy. Curr Cancer Drug Targets  2023,23(8),603-619","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","volume":"50","author":"Huang J.","year":"2022","unstructured":"Huang J.; Zheng L.; Sun Z.; Li J.; CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review). Int J Mol Med  2022,50(4),128","journal-title":"Int J Mol Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"Braal C.L.","year":"2021","unstructured":"Braal C.L.; Jongbloed E.M.; Wilting S.M.; Mathijssen R.H.J.; Koolen S.L.W.; Jager A.; Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: Similarities and differences. Drugs  2021,81(3),317-331","journal-title":"Drugs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/cells8091013","volume":"8","author":"Delou J.M.A.","year":"2019","unstructured":"Delou J.M.A.; Souza A.S.O.; Souza L.C.M.; Borges H.L.; Highlights in resistance mechanism pathways for combination therapy. Cells  2019,8(9),1013","journal-title":"Cells"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673385989250711112625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/244082\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673385989250711112625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T03:59:57Z","timestamp":1782705597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/244082\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673385989250711112625","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}